IMPLANTABLE PRODUCTS COMPRISING NANOPARTICLES

• US 20110223255A1
• Filed: 02/11/2009
• Published: 09/15/2011
• Est. Priority Date: 02/11/2008
• Status: Abandoned Application

• Current Assignee: Magforce AG
• Original Assignee: MagForce Nanotechnologies AG
• Inventors: Thiesen, Burghard, Jordan, Andreas
• Application Number:
  US12/864,793
• Publication Number:
  US 20110223255A1
• Time in Patent Office: Days
• US Class Current: 424/489
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 41/0028 Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
• CPC Class Codes: A61K 41/0052 Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61K 9/70 Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug hollow drug-filled fibres A61K9/0092
• CPC Class Codes: A61K 9/7015 Drug-containing film-forming compositions, e.g. spray-on
• CPC Class Codes: A61L 15/42 Use of materials characterised by their function or physical properties liquid bandages A61L26/00
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/604 Biodegradation
• CPC Class Codes: A61L 2300/80 characterised by a special chemical form
• CPC Class Codes: A61L 27/446 with other specific inorganic fillers other than those covered by A61L27/443 or A61L27/46
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 27/56 Porous materials, e.g. foams or sponges
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 41/00 Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present disclosure relates to nanoparticle-containing implantable and preferably biodegradable medical products and their use for the thermotherapeutic after-treatment after surgical removal of tumors and cancerous ulcers.

Claims

1. A solid or gel-like medical product heatable by an alternating magnetic field, wherein the medical product is provided in the form of a physiologically acceptable tissue, sponge, film or gel and wherein magnetic particles are contained in the medical product which will generate heat if excited by an alternating magnetic field and thereby will heat the medical product.

2. Medical product according to claim 1, wherein the particles are stationary embedded into or attached to the medical product.

3. Medical product according to claim 1, wherein the particles will remain permanently in the medical product, will not be released by diffusion and will only be released in the case of biodegradable medical products due to the degradation process.

4. Medical product according to claim 1, wherein the medical product is deformable and can be adjusted to the surface contours of a tissue or organ or the field of surgery after surgical tumor removal.

5. Medical product according to claim 1, wherein the medical product is biodegradable.

6. Medical product according to claim 1, wherein the particles are microparticles or nanoparticles.

7. Medical product according to claim 1, wherein the particles are paramagnetic or superparamagnetic.

8. Medical product according to claim 1, wherein the medical product is impregnated, coated or soaked with the magnetic particles.

9. Medical product according to claim 1, wherein the medical product is bioresorbable within one to twelve months.

10. Medical product according to claim 1, wherein the medical product is physiologically tolerated and is degraded to physiologically tolerated components.

11. Medical product according to claim 1, wherein the medical product is flexible and does not consist of a metal or a metal alloy and wherein the medical product is not provided in form of an aqueous solution of the particles.

12. Medical product according to claim 5, wherein the biodegradable medical product releases the magnetic particles and/or delivers them to surrounding tumor tissue or tumor cells.

13. Medical product according to claim 1, wherein the magnetic particles are provided at concentrations of 10 to 100 milligrams per square centimeter surface of the medical product.

14. Medical product according to claim 1, wherein the magnetic particles are provided at concentrations of 100 micrograms to 2 grams per gram of the medical product.

15. Medical product according to claim 1, wherein the medical product is medical cellulose, bandaging materials, wound inserts, surgical sutures, compresses, sponges, medical textiles, ointments, gels, film-forming compositions or film-forming sprays.

16. Medical product according to claim 1, further comprising at least one therapeutic effective agent selected from to group comprising anti-proliferative, anti-migratory, anti-angiogenic, anti-thrombotic, anti-inflammatory, anti-phlogistic, cytostatic, cytotoxic, anti-coagulative, anti-bacterial, anti-viral and/or anti-mycotic drugs, in particular wherein the at least one therapeutic active substance is selected from the group comprising actinomycin S, aminoglutethimide, arnsacrin, anastrozol, antagonists of purine or pyrimidine bases, anthracycline, aromatase inhibitors, asparaginase, anti-estrogens, bexaroten, bleomycin, buselerin, busulfan, camptothecin derivatives, capecitabin, carboplatin, carmustin, chlorambucil, cisplatin, cladribine, cyclophosphamide, cytarabine, cytosine arabinoside, alkylating cytostatics, dacarbazine, dactinomycin, daunorubicin, docetaxel, doxorubicin, epirubicin, estramustin, etoposide, exemestan, fludarabine, fluorouracil, folic acid antagonists, formestan, gemcitabine, glucocorticoids, goselerin, hormones and hormones antagonists, hycamtin, hydroxylurea, idarubicin, ifosfamide, imatinib, irinotecan, letrozol, leuprorelin, lomustin, melphalan, mercaptopurine, methotrexate, miltelosiii, mitomycin, mitosis inhibitors, mitoxantrone, nimustine, oxaliplatin, paclitaxel, pentostatin, procarbazine, tamoxifen, temozolomide, teniposide, testolacton, thiotepa, tioguanine, topoisomerase inhibitors, topotecan, treosulfan, tretinoin, triptorelin, trofosfamide, vinblastin, vincristin, vindesin, vinorelbin, cytostatically effective antibiotics.

18. Medical product according to claim 16, wherein the at least one drug is bound adhesively, ionically, covalently or via a linker to the particle.

19. Medical product according to claim 16, wherein the detachment of the at least one drug from the carrier is initiated by an alternating magnetic field.

20. Medical product according to claim 1, wherein the medical product consists of the following materials:

Polyacrylic acid, polyacrylate, polymethyl methacrylate, polybutyl methacrylate, polyisobutyl methacrylate, polyacrylamide, polyaerylnitrile, polyamide, polyetheramidc, polyethyleneamine, polyimide, polycarbonate, polycarbourethane, polyvinylketone, polyvinylhalogenide, polyvinylidenhalogenide, polyvinylether, polyvinyl aromatics, polyvinyl ester, polyvinylpyrollidone, polyoxymethylene, polyethylene, polypropylene, polytetrafluoroethylene, polyurethane, polyolefin elastomer, polyisobutylene, EPDM gums, fluorosilicone, carboxymethylchitosan, polyethylenetcrephtalate, polyvalerate, carboxymethylcellulose, cellulose, rayon, rayon triacetate, cellulose nitrate, cellulose acetate, hydroxyethyl cellulose, cellulose butyrate, cellulose acetate-butyrate, ethylvinylacetate copolymer, polysulfonc, polyethersulfone, epoxy resins, ABS resins, EPDM gums, silicone pre-polymer, silicone, polysiloxanc, polyvinyl halogen, cellulose ether, cellulose triacetate, chitosan, chitosan derivatives, polymerizable oils, polyvalerolactone, poly-ε

-decalacton, polylactide, polyglycolide, co-polymers of polylactide and polyglycolide, poly-ε

-caprolactone, polyhydroxy buturic acid, polyhydroxybutyrate, polyhydroxyvalerate, polyhydroxybutyrate-co-valerate, poly(1,4-dioxan-2,3-dione), poly(1,3-dioxan-2-one), polypara-dioxanonc, polyanhydridc, polymalcic acid anhydride, polyhydroxy methacrylate, polycyanoacrylate, polycaprolacton dimethylacrylate, poly-β

-maleic acid, polycaprolactonbutyl acrylate, multi-block polymers made of oligocaprolactonediol and oligodioxanondiol, polyetherester-multi-block polymers made of PEG and poly(butyleneterephtalate), polypivotolactone, polyglycolic acid trimethylcarbonate, polycaprolactone-glycolide, poly(γ

-ethylglutamate), poly(DTH-iminocarbonate), poly(DTE-co-DT-carbonate), poly(bisphenol A-iminocarbonate), polyorthoester, polyglycolic acid trimethyl-carbonate, polytrimethylcarbonate, polyimino carbonate, polyvinylic alcohols, polyester amides, glycolidized polyesters, polyphosphocsters, polyphosphazenes, poly[p-carboxyphenoxy)propane], polyhydroxypentaic acid, polyethylene oxide-propylene oxide, soft polyurethanes, polyurethanes with amino acid rests in the backbone, polyether esters, polyethylene oxide, polyalkenoxalates, polyorthoesters, carrageenans, starch, collagen, protein-based polymers, polyamino acids, synthetic polyamino acids, zein, modified zein, polyhydroxyalkanoates, pectic acid, actinic acid, fibrin, modified fibrin, casein, modified casein, carboxymethylsulphate, albumin, hyaluronic acid, heparan sulphate, heparin, chondroitin sulphate, dextrane, cyclodextrine, co-polymers made of PEG and polypropyleneglycol, gam arabic, guar, or other gum resins, gelatine, collagen, collagen-n-hydroxysuccinimide, lipids, lipoids, polymerizable oils and their modifications, co-polymers and mixtures of the aforementioned substancess.

21. Medical product according to claim 1 for use in medicine.

22. Use of the medical product according to claim 1 for the production of a means for prophylaxis, treatment and after-treatment of cancer, tumors and proliferative diseases, in particular for the after-treatment of an operative field in a cancer surgery.

24. Use of the medical product according to claim 22, wherein cancer, tumor or proliferative disease are selected from the group comprising:

Adenocarcinomas, choroid melanoma, acute leukemia, acoustic neurinoma, ampullary carcinoma, anal carcinoma, astrocytomas, basalioma, pancreatic carcinoma, connective tissue tumor, bladder cancer, bronchial carcinoma, non-small cell bronchial carcinoma, breast cancer, Burkitt'"'"'s lymphoma, corpus carcinoma, CUP syndrome, colon cancer, cancer of the small intestine, small intestine tumors, ovarian cancer, endometrial carcinoma, ependymoma, epithelial cancers, Ewing'"'"'s sarcoma, gastrointestinal tumors, gall-bladder cancer, bilary carcinomas, uterine cancer, cervical cancer, glioblastomas, gynecological tumors, otorhinolaryngologic tumors, hematologic neoplasias, urethral cancer, skin cancer, brain tumors (gliomas), brain metastases, testicular cancer, hypophyseal tumor, carcinoids, Kaposi'"'"'s sarcoma, laryngeal cancer, germinal tumor, bone cancer, colorectal carcinoma, head-neck tumors (tumors of neck, nose and ear areas), colon carcinoma, craniopharyngiomas, cancer of the mouth area and the lips, hepatic cancer, hepatic metastases, eyelid tumor, lung cancer, lymphatic gland cancer (Hodgkin/Non-Hodgkin), lymphomas, stomach cancer, malignant melanoma, malignant neoplasia, malignomas of the gastrointestinal tract, mammary carcinoma, rectal cancer, medulloblastomas, melanoma, meningeomas, Hodgkin'"'"'s disease, mycosis fungoides, nose cancer, neurinoma, neuroblastoma, kidney cancer, renal cell carcinoma, Non-Hodgkin'"'"'s lymphomas, oligodendroglioma, esophageal carcinoma, osteolytic carcinoma and osteoplastic carcinoma, osteosarcoma, ovarian carcinoma, pancreatic carcinoma, penile cancer, squamous cell carcinomas of the head and neck, prostate cancer, pharyngeal cancer, rectal carcinoma, retinoblastoma, vaginal cancer, thyroid carcinoma, Schneeberger'"'"'s disease, esophageal cancer, spinalioma, T-cell lymphoma (mycosis fungoides), thymoma, tubal carcinoma, eye tumors, urethral cancer, urologic tumors, urothelial carcinoma, vulvar cancer, mastoid involvement, soft tissue tumors, soft tissue sarcoma, Wilms'"'"' tumor, cervix carcinoma and tongue cancer.

17. (canceled)

23. (canceled)